Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication June 29, 2022
- Revision received November 14, 2022
- Published online April 28, 2023.
Article Versions
- previous version (January 19, 2023 - 12:04).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2023 by the Society of Nuclear Medicine and Molecular Imaging. Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: https://creativecommons.org/licenses/by/4.0/. Details: http://jnm.snmjournals.org/site/misc/permission.xhtml.
Author Information
- Julia Brosch-Lenz1,2,
- Astrid Delker1,
- Friederike Völter1,
- Lena M. Unterrainer1,
- Lena Kaiser1,
- Peter Bartenstein1,
- Sibylle Ziegler1,
- Arman Rahmim2,3,4,
- Carlos Uribe3,5 and
- Guido Böning1
- 1Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany;
- 2Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, British Columbia, Canada;
- 3Department of Radiology, University of British Columbia, Vancouver, British Columbia, Canada;
- 4Department of Physics, University of British Columbia, Vancouver, British Columbia, Canada; and
- 5Department of Functional Imaging, BC Cancer, Vancouver, British Columbia, Canada
- For correspondence or reprints, contact Julia Brosch-Lenz (jbrosch{at}bccrc.ca).
Statistics from Altmetric.com
Cited By...
Article usage
In this issue
Jump to section
Related Articles
Cited By...
- Characterization of Effective Half-Life for Instant Single-Time-Point Dosimetry Using Machine Learning
- An International Study of Factors Affecting Variability of Dosimetry Calculations, Part 4: Impact of Fitting Functions in Estimated Absorbed Doses
- Impact of Posttreatment SPECT/CT on Patient Management During 177Lu-PSMA-617 Radiopharmaceutical Therapy
- Impact of the Reference Multiple-Time-Point Dosimetry Protocol on the Validity of Single-Time-Point Dosimetry for [177Lu]Lu-PSMA-I&T Therapy
- Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT Imaging at 24 Hours After Injection
- Single-Time-Point Renal Dosimetry Using Nonlinear Mixed-Effects Modeling and Population-Based Model Selection in [177Lu]Lu-PSMA-617 Therapy
- Renal and Multiorgan Safety of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy